Activation of c-Met can overcome EGFR blockade in preclinical models of HNSCC and in HNSCC patients [40,94,95], thereby identifying the HGF/c-Met pathway as a potential node of resistance to EGFR-targeted therapies in HNSCC. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.